MDAI ROSECLIFF ACQUISITION CORP I

Spectral AI Names Industry Veteran and Former Top MiMedx Financial Executive Peter M. Carlson as CFO

Spectral AI Names Industry Veteran and Former Top MiMedx Financial Executive Peter M. Carlson as CFO

DALLAS, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, announced the hiring of Peter M. Carlson as Chief Financial Officer today.

“As the new CFO of Spectral AI, Pete brings an exceptional track record as a senior financial executive at several public companies in multiple industries, including two Fortune 50 entities, and most recently at a healthcare company focused on chronic and hard-to-heal wounds. A highly qualified and a respected leader, Pete has made a difference by leading critical strategic partnerships, driving significant creative financial transactions, and leveraging deep relationships in the capital markets,” said Spectral AI CEO Wensheng Fan. “As Spectral AI embarks on introducing its innovative technologies to the market, Pete's extensive expertise will be invaluable as we navigate the complexities of the financial landscape and strategic opportunities, while propelling the Company to new heights.”

“I am excited to work with Wensheng and the team at Spectral AI, which has game-changing healthcare technology in the acute and chronic wound care space that I anticipate will improve the quality of patient care and reduce costs in the overall healthcare system. The growth and value potential for Spectral AI are significant,” said Mr. Carlson. “My focus will be on informing investors and capital providers about the business opportunities made possible by the breakthrough technology the team developed.”

Mr. Carlson most recently served as CFO at MiMedx Group, Inc., a pioneer and leader in the advanced wound care space. Prior to his work at MiMedx, Mr. Carlson served as Chief Operating Officer at Brighthouse Financial, Inc., and played an essential role in establishing Brighthouse as a separate public company after its spin-off from MetLife, Inc., where he worked for eight years. At MetLife, as Chief Accounting Officer, he led accounting, tax and financial reporting activities, along with budgeting and financial planning. Prior to MetLife, Pete was the Controller at Wachovia Corporation and an audit partner for a Big Four accounting firm. Mr. Carlson serves as a Board Member at White Mountains Insurance Group and as a trustee for Wake Forest University. He is a certified public accountant in New York and North Carolina, and he received a Bachelor of Science from Wake Forest University.

Carlson will succeed Nils Windler, who will remain with Spectral AI to work closely with Mr. Carlson, support an orderly transition of responsibilities and provide financial accounting support to the Company.

About Spectral AI

Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns and diabetic foot ulcers. The Company is working to revolutionize the management of wound care by “Seeing the Unknown®” with its DeepView® System. DeepView® is a predictive diagnostic device that offers clinicians an objective and immediate assessment of a wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of substantially exceeding the current standard of care in the future, DeepView® is expected to provide faster and more accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. For more information about DeepView®, visit .

Forward Looking Statements

Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements.

These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements.

Investors should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the SEC, including the Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements.

Contacts:

Investors:

The Equity Group

Devin Sullivan

Managing Director

Conor Rodriguez

Analyst

Media:

Russo Partners

David Schull

Russo Partners

(858) 717-2310



EN
19/12/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ROSECLIFF ACQUISITION CORP I

 PRESS RELEASE

Spectral AI Announces Submission to FDA of its DeepView® System

Spectral AI Announces Submission to FDA of its DeepView® System DALLAS, June 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration (“FDA”) in 2018 and uses multi-spectral imaging and artificial intelligence (“AI”) algorithms to predict burn healing potential, today announced the submission of its De Novo 510k marketing clearance application to the FDA for the DeepView System, intended for use in burn care settings, inclu...

 PRESS RELEASE

DeepView® System highlighted at the annual British Burn Association co...

DeepView® System highlighted at the annual British Burn Association conference DALLAS, June 10, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced its prominent role at the annual British Burn Association (BBA) conference, held from June 4th – 6th in Brighton, UK. The Company was featured in multiple presentations, highlighting its contributions to advancing burn care across the globe. Key Presentat...

 PRESS RELEASE

Spectral AI Announces Appointment of Stanley Micek as Chief Operating ...

Spectral AI Announces Appointment of Stanley Micek as Chief Operating Officer DALLAS, May 30, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that Stanley Micek has been named the Company’s Chief Operating Officer (“COO”). Micek’s promotion reflects his role change from Interim COO of the Company since May, 2024 “Stan has demonstrated exceptional leadership, operational insight, and a deep unde...

 PRESS RELEASE

Spectral AI Announces Voting Results from 2025 Annual Meeting of Stock...

Spectral AI Announces Voting Results from 2025 Annual Meeting of Stockholders DALLAS, May 29, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, announced results from its 2025 Annual Meeting of Stockholders held earlier today. A total of 15,551,068 shares representing 60.8% of the Company’s total shares outstanding were represented at the meeting, either in person or by proxy. Both of the proposals set forth by the...

 PRESS RELEASE

DeepView® System Achieves 95.3% Accuracy Evaluation as Published in Bu...

DeepView® System Achieves 95.3% Accuracy Evaluation as Published in Burns Journal DALLAS, May 27, 2025 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASDAQ: MDAI) (“Spectral AI” or the “Company”), a leading developer of the AI-driven DeepView® System, which uses multi-spectral imaging and AI algorithms to predict burn healing potential today announced that the Company’s DeepView System has been featured in the journal Burns as part of a clinical study in which it achieved a 95.3% overall accuracy assessment as compared to traditional subjective assessments. Chris Lewis, a lead author of the...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch